Cargando…

728. Activity of Eravacycline Against Contemporary Gram-Negative Clinical Isolates From New York City Hospitals

BACKGROUND: Antibiotic-resistant Gram-negative bacteria, including KPC-producing Enterobacteriaceae and carbapenem-resistant A. baumannii, have been problematic hospital pathogens in NYC and other areas. Eravacycline (ERV), a fluorocycline antibiotic released in the USA in 2018, has demonstrated in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iregui, Alejandro, Khan, Zeb, Landman, David, Quale, John M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811199/ http://dx.doi.org/10.1093/ofid/ofz360.796

Ejemplares similares

695. Activity of Imipenem–Relebactam and Ceftolozane–Tazobactam Against a Contemporary Collection of Gram-Negative Bacteria from New York City
por: Iregui, Alejandro, et al.
Publicado: (2019)

721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City
por: Iregui, Alejandro, et al.
Publicado: (2019)

Activity of Cefiderocol Against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Endemic to Medical Centers in New York City
por: Iregui, Alejandro, et al.
Publicado: (2020)

253 Activity of Eravacycline Against Enterobacteriaceae and Acinetobacter baumannii from New York City
por: Abdallah, Marie, et al.
Publicado: (2014)

249 Activity of Plazomicin Against Contemporary Isolates of Enterobacteriaceae from New York City
por: Olafisoye, Olawole, et al.
Publicado: (2014)

629. Emergence and Clonal Spread of Delafloxacin-Resistant S. aureus in Brooklyn, NY
por: Malik, Saquib, et al.
Publicado: (2019)

1613. Global 2018 Surveillance of Eravacycline Against Gram-negative Pathogens, Including Multi-drug Resistant Isolates
por: Lijfrock, Virgil, et al.
Publicado: (2020)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in vitro Study
por: Zou, Xuehan, et al.
Publicado: (2023)

In Vitro Activity of Eravacycline against Carbapenemase-Producing Gram-Negative Bacilli Clinical Isolates in Central Poland
por: Brauncajs, Małgorzata, et al.
Publicado: (2023)

In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
por: Morrissey, Ian, et al.
Publicado: (2020)

334 Emergence of OXA-23-possessing Acinetobacter baumannii in Hospitals in New York City
por: Abdallah, Marie, et al.
Publicado: (2014)

2132. Multicenter Evaluation of Eravacycline MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative MIC Panels
por: Traczewski, Maria M, et al.
Publicado: (2019)

728. Genomic Characterization of Burkholderia pseudomallei Isolates in Colombia
por: Espitia-Acero, Catalina, et al.
Publicado: (2021)

1802 Prevalence of KPC-possessing Klebsiella pneumoniae in New York City: Have We Turned the Corner?
por: Abdallah, Marie, et al.
Publicado: (2014)

2133. Surveillance of Eravacycline Against Gram-positive Clinical Pathogens, Including Resistant Isolates, Collected Worldwide From Multiple Infection Sites During 2021
por: Hawser, Stephen, et al.
Publicado: (2023)

1259. Activity of eravacycline against staphylococci isolated from periprosthetic joint infections
por: Zhuchenko, Georg, et al.
Publicado: (2020)

In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017
por: Morrissey, Ian, et al.
Publicado: (2020)

In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of Bacteroides Species.
por: Citron, Diane, et al.
Publicado: (2017)

1485. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Contemporary (2015–2017) Gram-Negative Isolates from Patients with Pneumonia in US Medical Centers
por: Arends, S J Ryan, et al.
Publicado: (2018)

1243. Eravacycline in Bacteremia: A Case Series
por: Andrade, Justin A, et al.
Publicado: (2021)

728. Regional Validation of Distinct RSV Seasonality Thresholds for Antigen and PCR Testing
por: Ambrose, Christopher S, et al.
Publicado: (2018)

688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile
por: Basseres, Eugenie, et al.
Publicado: (2019)

A population-based study examining the emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 in New York City
por: Bratu, Simona, et al.
Publicado: (2006)

In Vitro and In Vivo Activity of Single and Dual Antimicrobial Agents Against KPC-producing Klebsiella pneumoniae
por: Moussavi, Farzad, et al.
Publicado: (2017)

1430. Eravacycline associated hypofibrinogenemia during treatment of M.abscessus
por: Rausch, Ethan, et al.
Publicado: (2022)

2132. Surveillance of Eravacycline Against Enterobacterales and Non-Fermenter Clinical Isolates, Including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2021
por: Hawser, Stephen, et al.
Publicado: (2023)

PT728. Potentially inappropriate medications in the elderly in Korean long-term care facilities
por: Lee, Kang Soo
Publicado: (2016)

331. Five Cases of Hemophagocytic Lymphohistiocytosis in Patients with HIV: A Fulminant and Lethal Combination
por: Bhatt, Isha, et al.
Publicado: (2019)

710. In Vitro Activity and Performance of Available Susceptibility Testing Methods for Eravacycline Against Carbapenem-Resistant Enterobacteriaceae (CRE)
por: Jones, Chelsea E, et al.
Publicado: (2019)

728. Potential Reservoirs for Additional Carbapenemase Gene Spread: Detection of Carbapenemase Genes in non-Pseudomonas aeruginosa and non-Acinetobacter baumannii isolates
por: Sabour, Sarah, et al.
Publicado: (2023)

1577. Real-World, Multicenter Experience with Eravacycline for Various Infections
por: Alosaimy, Sara, et al.
Publicado: (2020)

Pharmacokinetics (PK) of Eravacycline in Subjects with Renal or Hepatic Impairment Compared with Healthy Subjects
por: Horn, Patrick, et al.
Publicado: (2017)

633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2022)

390. Eravacycline combination therapy for severe, recurrent, or fulminant Clostridioides difficile infection
por: Morrison, Austin R, et al.
Publicado: (2022)

In vitro Susceptibility Testing of Essential Oils against Gram-positive and Gram-negative Clinical Isolates, including Carbapenem-resistant Enterobacteriaceae (CRE)
por: Patterson, Jan E, et al.
Publicado: (2017)

Streptococcus pneumoniae, Brooklyn, New York: Fluoroquinolone Resistance at our Doorstep
por: Quale, John, et al.
Publicado: (2002)

560. Repurposing Eravacycline for the Treatment of SARS-CoV-2 Infections
por: Reig, Núria, et al.
Publicado: (2020)

1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients
por: Rolston, Kenneth V I, et al.
Publicado: (2018)

P35 Heteroresistance to cefiderocol in clinical Gram-negative isolates
por: Watson, Celeste, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sqhfub2eodemjkfic4g35cpiub